JCS/T2D - We are advocates. We learn. We share. We inform.

Summary

Eli Lilly’s tirzepatide has shown remarkable potential in reducing the risk of type 2 diabetes by 94% in overweight and obese adults, according to new data from the SURMOUNT-1 study. This breakthrough not only highlights tirzepatide's effectiveness in diabetes prevention but also its significant impact on weight loss.

Key Points

• 94% Risk Reduction: Tirzepatide reduces the risk of developing type 2 diabetes by 94% in adults with obesity or overweight.
• Significant Weight Loss: Participants experienced an average weight reduction of 22.9% with the highest dose.
• Dual Mechanism: Tirzepatide works by activating both GIP and GLP-1 receptors, regulating appetite and improving insulin sensitivity.
• Long-Term Study: The SURMOUNT-1 study is the longest trial of its kind, lasting 176 weeks.
• Broader Implications: This drug could reshape strategies for managing obesity and preventing type 2 diabetes on a global scale.

Pharmaceutical leaders Eli Lilly and Novo Nordisk are making significant investments to expand their manufacturing capacities for GLP-1 drugs, which are crucial for diabetes and obesity treatments. Eli Lilly is dedicating an additional $5.3 billion to its Indiana site, aiming to address current drug shortages and enhance production of tirzepatide (marketed as Mounjaro and Zepbound). Concurrently, Novo Nordisk is investing $4.1 billion in its North Carolina facility to boost the production of injectable treatments. These efforts highlight the companies' commitment to meeting the growing global demand for these essential medications and ensuring a stable supply chain.

Key Points

• Eli Lilly's Investment: An additional $5.3 billion is being invested in the Lebanon, Indiana site to produce active pharmaceutical ingredients for tirzepatide (Mounjaro and Zepbound).
• Novo Nordisk's Expansion: A $4.1 billion investment is directed towards the Clayton, North Carolina facility to increase production of diabetes and obesity treatments.
• Economic Impact: Eli Lilly's investment will create 200 full-time jobs and over 5,000 construction jobs, contributing to economic growth in Indiana.
• Sustainable Practices: Novo Nordisk aims for LEED Gold certification for its facility, incorporating state-of-the-art technology and sustainable practices.
• Addressing Drug Shortages: Both companies are focused on alleviating current shortages and ensuring a more stable supply chain for GLP-1 drugs.

Abstract

The FDA has issued a warning regarding dosing errors with compounded semaglutide injectable products, stressing significant risks for patients managing type 2 diabetes and using semaglutide for weight loss. Unlike FDA-approved versions, compounded semaglutide varies in concentration and dosing instructions, leading to potential overdoses and severe adverse effects. Clear communication and proper dosing tools are essential to ensure patient safety.

Key Points

1. FDA Warning: Alert on dosing errors with compounded semaglutide, noting overdoses and severe side effects.
2. FDA-Approved vs. Compounded: Compounded versions vary in concentration and instructions, unlike standardized FDA-approved products.
3. Common Errors: Misunderstandings in measurement units and inappropriate syringe use lead to significant overdoses.
4. Case Examples: Patients and providers often miscalculate doses, resulting in severe adverse effects.
5. Recommendations: Emphasize clear communication, proper dosing tools, and double-checking calculations.
6. Summary: Use FDA-approved products and consult healthcare professionals to avoid risks. Report adverse effects to FDA’s MedWatch.